News

Oegstgeest, April 22, 2025 – MIMETAS published a new peer-reviewed study detailing a significant advancement in vascular disease modeling. The paper, titled “Microfluidic artery-on-a-chip model with unidirectional gravity-driven flow for high-throughput applications”, introduces a novel in vitro model that replicates the physiological and pathological behavior of human arteries.

Leiden, Netherlands, February 17, 2025 – A new study published in Toxins presents a multi-parametric approach to assess barrier disruption in advanced 3D human gut models. The research uses candidalysin, a cytolytic peptide toxin produced by Candida albicans, as a model compound to investigate epithelial damage.

Leiden, January 27, 2025 — Leiden, Netherlands, January 27, 2025 — MIMETAS, a global leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts as a key addition to MIMETAS’ service portfolio.

Leiden, October 24, 2024 — Researchers from MIMETAS and Sanofi have published a study on an immunocompetent human kidney-on-a-chip model.

Leiden, October 24, 2024 – MIMETAS has announced a breakthrough publication in Biofabrication, unveiling a new microvascularized in vitro liver model. This innovation represents a critical leap forward in drug discovery and disease research, addressing longstanding challenges in replicating liver function in non-clinical settings.

Leiden, September 8, 2024 – MIMETAS has introduced the OrganoReady® Colon Organoid, a first-of-its-kind, ready-to-use 3D colon model derived from adult stem cells. Designed to advance gastrointestinal toxicity screening, this high-throughput model offers seamless integration into laboratory workflows, streamlining drug development.

Leiden, September 6, 2024 – Researchers from MIMETAS, Roche, and Eberhard Karls University Tübingen publish a new review on the potential of microphysiological systems (MPS) in toxicity testing for new drug modalities.

Leiden, July 11, 2024 – MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, announce an Investigational New Drug (IND) filing by argenx, supported by data from MIMETAS.

Leiden, July 7, 2024 – Project SECRET, an innovative doctoral network under the Horizon Europe programme - Marie Skłodowska-Curie Action, has been awarded significant EU funding of €2.5 million. This funding will drive groundbreaking research focused on the therapeutic potential of perinatal cell secretomes for treating neurological and cardiovascular disorders.

Leiden, June 4, 2024 – Scientists from MIMETAS, Naturalis Biodiversity Center and Vrije Universiteit Amsterdam provide groundbreaking insights into the treatment of snakebite toxicity. The research introduces an assay using an automated 3D blood vessel model that mimics human endothelial tubules to study the hemorrhagic effects of snake venoms in real-time.

Utrecht, 15 March 2024 –The Dutch National Growth Fund will invest 124.5 million euros in a new centre for animal-free biomedical testing, known as the Centre for Animal-Free Biomedical Translation.

Amsterdam, March 15, 2024 – The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into 'microbiomes' and economically interesting applications thereof.

Leiden, March 11, 2024 – Researchers from MIMETAS have unveiled a study to address the detrimental effects of enterotoxins on the human intestinal epithelium using a high-throughput gut-on-a-chip platform.

Utrecht, February 5, 2024 – MIMETAS, a global leader in organ-on-chip-based disease models, is playing a pivotal role in the GRIPonMASH initiative, a newly established consortium dedicated to transforming the detection and treatment of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).

Leiden, 29 November 2023 — MIMETAS, a leader in human 3D disease modeling, and Yamaha Motor Co., Ltd., a developer of the CELL HANDLER^TM, announce a strategic joint marketing partnership aimed at advancing therapeutic development using human-relevant models throughout the early drug development pipeline.

Leiden, November 27, 2023 – Researchers from MIMETAS and Amsterdam UMC have published an article on advancements in microfluidic in vitro modeling of the blood-brain barrier (BBB) and neurovascular unit (NVU). Their work was published in Fluids and Barriers of the CNS.

The Hague, November 2, 2023 – Netherlands Academy of Engineering nominates MIMETAS CEO, Paul Vulto as a new Fellow, alongside 61 others, to actively contribute to their mission. This nomination emphasizes the crucial role of innovative technological solutions in addressing pressing societal challenges and sustainable change.

Leiden, September 14, 2023 – MIMETAS Scientists established a high-throughput human BBB-on-a-chip to study neuroinflammation and transendothelial migration.

Leiden, August 1, 2023 – MIMETAS researchers report the first large-scale phenotypic screen utilizing Organ-on-a-Chip (OoC) technology. This groundbreaking study was published in the Journal of Angiogenesis.

Leiden July 14, 2023 - A placenta on a chip developed at the University of Dundee has the potential to transform research into life-threatening conditions in pregnancy.

Utrecht, 30 June 2023 - The Center for Animal-Free Biomedical Translation (CPBT) is planning to accelerate the transition to animal-free biomedical innovations. This should offer economic and social benefits: improved medicines and fewer animal tests. MIMETAS (Leiden, The Netherlands), the renowned leader in human tissue and disease modeling using organ-on-a-chip technologies, proudly announces its partnership in the CPBT consortium, focusing on ALS, lower back pain, and protein transition & food allergy. This collaboration marks a significant step towards advancing pharmaceutical, chemical, and food component development while minimizing reliance on animal testing.

Leiden June 20, 2023 – MIMETAS, a global leader in human disease modeling announces that it has expanded its ongoing partnership with Astellas, a global pharmaceutical company, to include automation and application support.

Leiden, May 10, 2023 – MIMETAS scientists develop and characterize a pancreatic ductal adenocarcinoma (PDAC) model and applied it to study the role of the endothelium and the stroma in immune cell migration.

Leiden, May 5, 2023 – MIMETAS researchers develop an in vitro model of the placental barrier, which could aid in understanding preeclampsia (PE) and other placental pathologies associated with hypoxia/ischemia.

Leiden, March 28, 2023 – MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.

Leiden, March 22, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus Infections (HBV).

Leiden, March 7, 2023 - MIMETAS announces that it has launched its Adult Stem Cell-derived Colon and Kidney tubular organoids in an assay ready format.

Leiden, February 24, 2023 – MIMETAS scientists shed light on the potential role of gut-on-a-chip models for studying host-microbial interactions in the context of intestinal physiology.

Leiden, February 3, 2023 – MIMETAS scientists established a 3D Pancreatic Ductal Adenocarcinoma (PDAC) model, enabling the study of cancer treatment response in PDAC organoids.

Leiden, November 2, 2022 – MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.

LEIDEN, September 8, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.

Leiden, February, 2022 – TEDxBoerhaavedistrictStudio guides us through a virtual ‘Walk in the Park’ with inspiring TEDx speakers from the Boerhaavedistrict in Leiden, The Netherlands. This month, Jos Joore (MIMETAS’ CEO) explains why the development of pharmaceuticals is a hugely expensive and uncertain process and offers a possible solution for more efficient drug development.

December 10, 2020 – To put new developments in 3D tissue biology in the limelight, MIMETAS organizes 3D-cember every 3rd of December. Videos of the 2020 live-streamed edition are now available on-demand.

January 23, 2020 – The Hubrecht institute and MIMETAS investigated if venom molecules produced by snake venom gland organoids also function as actual venom using the OrganoPlate^® platform.

March 5, 2019 – Leading stem cell research group and global leader in organ-on-a-chip technology develop stem cell-derived kidney tubules in microfluidic chips.

April 11, 2018 – Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new product development.